keyword
MENU ▼
Read by QxMD icon Read
search

ABVD

keyword
https://www.readbyqxmd.com/read/29159711/treatment-of-richter-s-syndrome
#1
REVIEW
Adalgisa Condoluci, Davide Rossi
Based on the available literature, mostly derived from retrospective or non-randomized phase I or II studies, it is difficult to define an optimized treatment approach for patients developing Richter's syndrome (RS). Early recognition of chronic lymphocytic leukemia (CLL) patients presenting clinical features suspected for a transformation is useful to avoid exposing them to multiple lines of therapy that, being targeted to CLL progression, have poor efficacy against RS. Because of the low specificity (~ 50-60%) of clinical signs of RS (such as rapid and discordant bulky localized lymphadenopathies, elevated LDH levels, emergent physical deterioration, and/or fever in the absence of infection), a (18)FDG PET/CT and a biopsy are recommended to confirm RS...
November 21, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29158727/near-complete-response-in-a-patient-with-classical-hodgkin-lymphoma-treated-with-brentuximab-vedotin-concurrent-with-radiation-therapy
#2
Wilbur Montana, Dennis Andrew Buck, Tristan Smith
Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior multi-agent chemotherapy regiments. This approval was based on a study that showed an overall response rate of 75% and complete remission in 34%. We present a case of a 24-year-old male with classical nodular sclerosing Hodgkin lymphoma who achieved near complete remission following 5 cycles of brentuximab concurrent with ISRT (involved site radiation therapy) following progression of first-line ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) and subsequent second-line ICE (ifosfamide, carboplatin, etoposide) chemotherapy...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29156707/infradiaphragmatic-hodgkin-lymphoma-a-large-series-of-patients-staged-with-pet-ct
#3
Cédric Rossi, Morgane Mounier, Pauline Brice, Violaine Safar, Emmanuelle Nicolas-Virelizier, Philippe Rey, Aspasia Stamatoullas-Bastard, Marion Alcantara, Adrien Chauchet, Emilie Reboursière, Lauriane Filliatre, Aurore Perrot, Sylvain Garciaz, Gilles Salles, Bertrand Coiffier, Hervé Ghesquières, René-Olivier Casasnovas
Introduction: Infradiaphragmatic Hodgkin Lymphoma (IDHL) accounts for 3-11% of adult cases of stage I-II Hodgkin Lymphoma and the treatment strategy in IDHL is still heterogeneous. All previous published studies were conducted before the PET-CT era. PET may provide a more accurate evaluation of IDHL stage. The aim of this study was to analyze the clinical and biological characteristics of IDHL patients staged by CT scan or PET-CT in eight French hematology departments and their impact on outcomes in these patients...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29138655/endobronchial-localization-of-hodgkin-s-disease
#4
Lamyae Amro, Siham Jridi, Hafsa Sajiai, Hind Serhane, Salma Aït Batahar
The endobronchial localization of Hodgkin's disease is a rare entity which is often confused with endobronchial tuberculosis in our setting. We report the case of a 16 years old female who presented with 6 months history of dry cough, hemoptysis, dyspnea, dysphagia and dysphonia. The chest radiography showed a mediastinal and pulmonary opacity. The chest CT scan found enlarged mediastinal lymph nodes. The bronchial biopsy and peripheral lymph node biopsy confirmed Hodgkin's disease with endobronchial localization...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/29108389/hodgkin-lymphoma-in-adolescent-and-young-adults-insights-from-an-adult-tertiary-single-center-cohort-of-349-patients
#5
Camille Bigenwald, Jacques-Emmanuel Galimard, Laurent Quero, Aurélie Cabannes-Hamy, Catherine Thieblemont, Nicolas Boissel, Pauline Brice
Background: Adolescent and young adults (AYA) represent one third of patients affected by Hodgkin lymphoma (HL). These patients are frequently treated either with pediatric or adult protocol depending on their physician background. This population has been understudied so far, in terms of HL characteristics and treatment-associated outcomes. Aim: We aimed to extensively describe HL features in the AYA population including HL characteristics, progression-free (PFS) and overall survival (OS)...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29041005/cardiogenic-shock-during-first-infusion-of-anthracycline-chemotherapy-in-a-patient-with-hodgkin-lymphoma-an-unusual-event
#6
Giulio Binaghi, Damiana Congia, Stefano Cossa, Stefania Massidda, Daniele Pasqualucci, Federica Pilo, Emanuela Serra, Emanuele Angelucci, Maurizio Porcu
INTRODUCTION: Hodgkin lymphoma (HL) is one of the most common types of cancers of the lymphatic system. The currently available therapies enable a cure in approximately 80-85% of treated patients. However, the cardiotoxicity of HL treatment has become a major cause of morbidity and mortality in survivors mainly related to the use of anthracycline. CASE REPORT: An HL, staged IIIB, was diagnosed in a 60-year-old man with no cardiovascular disease. During the first cycle of ABVD chemotherapy (Adriamycin; bleomycin; vinblastine; dacarbazine), near the end of the dacarbazine infusion, the patient presented a sudden cardiogenic shock characterized by a severe left ventricular systolic dysfunction...
October 18, 2017: Cardiology
https://www.readbyqxmd.com/read/29023692/lower-socioeconomic-status-is-independently-associated-with-shorter-survival-in-hodgkin-lymphoma-patients-an-analysis-from-the-brazilian-hodgkin-lymphoma-registry
#7
Irene Biasoli, Nelson Castro, Marcia Delamain, Talita Silveira, James Farley, Belinda Pinto Simões, Cristiana Solza, Monica Praxedes, Otávio Baiocchi, Rafael Gaiolla, Fernanda Franceschi, Caroline Bonamin Sola, Carla Boquimpani, Nelma Clementino, Guilherme Fleury Perini, Kátia Pagnano, Giovana Steffenello, Jacques Tabacof, Gilberto de Freitas Colli, Andrea Soares, Carmino de Souza, Carlos Sérgio Chiattone, Ronir Raggio Luiz, Cristiane Milito, José Carlos Morais, Nelson Spector
Socioeconomic status (SES) is a well-known determinant of outcomes in cancer. The purpose of this study was to analyze the impact of the SES on the outcomes of Hodgkin lymphoma (HL) patients from the Brazilian Prospective HL Registry. SES stratification was done using an individual asset/education-based household index. A total of 624 classical HL patients with diagnosis from January/2009 to December/2014, and treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), were analyzed. The median follow-up was 35...
October 11, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28992524/early-reduction-of-serum-tarc-levels-may-predict-for-success-of-abvd-as-frontline-treatment-in-patients-with-hodgkin-lymphoma
#8
A Guidetti, A Mazzocchi, R Miceli, E Paterno', F Taverna, F Spina, F Crippa, L Farina, P Corradini, A M Gianni, S Viviani
BACKGROUND: Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. METHODS: Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values...
November 2017: Leukemia Research
https://www.readbyqxmd.com/read/28953683/classic-hodgkin-lymphoma-in-pelvis-a-case-report-highlights-diagnosis-and-treatment-challenges
#9
Fan Tang, Li Min, Yunxia Ye, Bo Tang, Yong Zhou, Wenli Zhang, Chongqi Tu
RATIONALE: Classic Hodgkin lymphoma with pelvic involvement is a rare entity. Diagnosis and treatment for such an uncommon disease are challenging. Here we report a special case of classic Hodgkin lymphoma in pelvis. PATIENT CONCERNS: A 20-year-old woman was admitted to our department due to left hip symptoms. The patient reported a history of drenching night sweats, low-grade fever, pruritic rash on the body, and an almost 15% weight loss during the previous 3 months...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28950332/the-predictive-role-of-interim-pet-after-the-first-chemotherapy-cycle-and-sequential-evaluation-of-response-to-abvd-in-hodgkin-lymphoma-patients-the-polish-lymphoma-research-group-plrg-observational-study
#10
J M Zaucha, B Malkowski, S Chauvie, Subocz E, J Tajer, Kulikowski W, A Fijolek-Warszewska, A Biggi, F Fallanca, M Kobylecka, M Dziuk, D Woszczyk, J Rybka, R Kroll-Balcerzak, F Bergesio, A Romanowicz, A Chamier-Cieminska, P Kurczab, A Giza, K Lesniewski-Kmak, R Zaucha, D Swietlik, T Wróbel, W Knopinska-Posluszny, J Walewski, A Gallamini
Background: Interim PET after 2 ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin lymphoma (cHL). To test if an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value (PV) of iPET after 1 ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning. Patients and Methods: Consecutive patients with newly diagnosed cHL underwent interim PET scan after one ABVD course (iPET1)...
September 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28937297/clinical-outcome-of-patients-with-early-stage-favorable-hodgkin-lymphoma-treated-with-abvd%C3%A2-%C3%A3-%C3%A2-two-cycles-followed-by-fdg-pet-ct-restaging-and-20%C3%A2-gy-of-involved-site-radiotherapy
#11
Sophia C Kamran, Heather A Jacene, Yu-Hui Chen, Peter M Mauch, Andrea K Ng
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT assessment and involved-site radiotherapy (ISRT) to 20 Gy. Records of 23 patients who met eligibility criteria, treated between 2008 and 2016, were reviewed. PET response after two cycles of ABVD was independently assessed by a nuclear medicine physician. After two cycles of ABVD, 91...
September 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28932610/pneumocystis-pneumonia-in-non-hiv-pregnant-women-receiving-chemotherapy-for-malignant-lymphoma-two-case-reports
#12
Yuki Fukutani, Yoshitsugu Chigusa, Eiji Kondoh, Kaoru Kawasaki, Shingo Io, Noriomi Matsumura
Pneumocystis pneumonia (PCP) is a life-threatening opportunistic infection that sometimes occurs in immunocompromised patients with human immunodeficiency virus (HIV). Here, we report two extremely rare cases of PCP in non-HIV pregnant women who underwent chemotherapy for malignant lymphoma. Case  1 is a 34-year-old primigravida who was diagnosed with Hodgkin's lymphoma. She received ABVD chemotherapy and developed PCP at 37 weeks of gestation. After the onset of PCP, emergent cesarean section was performed due to a nonreassuring fetal status...
2017: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28927453/employment-status-and-health-related-quality-of-life-among-hodgkin-lymphoma-survivors-results-based-on-data-from-a-major-treatment-center-in-hungary
#13
Ferenc Magyari, Karolina Kósa, Roland Berecz, Anna Illés, Zsófia Miltényi, Zsófia Simon, Árpád Illés
BACKGROUND: Due to risk and response adapted treatment strategies, more than 80% of newly diagnosed classical Hodgkin lymphoma (HL) patients can be cured, and become long-term survivors. However, a high proportion of survivors suffer from treatment-related long-term side effects such as secondary malignancy, organ failure, persistent fatigue and psychological distress. The aim of this study was to evaluate psychological distress and its risk factors among our HL survivors. METHODS: One hundred sixty-three (50% female) adult HL survivors were contacted between January 1, 2012 and march 31, 2015 in our outpatient centre...
September 19, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28912294/brentuximab-is-it-time-for-a-new-b-in-abvd
#14
Deborah M Stephens
No abstract text is available yet for this article.
September 14, 2017: Blood
https://www.readbyqxmd.com/read/28902084/children-and-adolescent-hodgkin-lymphoma-in-argentina-long-term-results-after-combined-abvd-and-restricted-radiotherapy
#15
Pedro A Zubizarreta, Elizabeth Alfaro, Myriam Guitter, Cristian Sanchez La Rosa, María L Galluzzo, Natalia Millán, Fernando Fiandrino, María S Felice
OBJECTIVE: Prospective analysis of clinical characteristics and long-term treatment results of a pediatric cohort with Hodgkin lymphoma (HL) treated in a single institution with ABVD and restricted radiotherapy (RT). PATIENTS AND METHODS: Between September 2000 and December 2015, 165 new consecutive assessable patients with HL were registered at our institution. Lymphocyte predominant nodular HL was excluded. Low risk (LR) patients were stage I and IIA (no bulky disease, <4 involved ganglionar areas and no lung hilar nodes), high risk (HR) was assigned to stage IV and any other stage with bulky mediastinum...
November 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28901021/optimisation-of-chemotherapy-and-radiotherapy-for-untreated-hodgkin-lymphoma-patients-with-respect-to-second-malignant-neoplasms-overall-and-progression-free-survival-individual-participant-data-analysis
#16
REVIEW
Jeremy Franklin, Dennis A Eichenauer, Ingrid Becker, Ina Monsef, Andreas Engert
BACKGROUND: Efficacy and the risk of severe late effects have to be well-balanced in treatment of Hodgkin lymphoma (HL). Late adverse effects include secondary malignancies which often have a poor prognosis. To synthesise evidence on the risk of secondary malignancies after current treatment approaches comprising chemotherapy and/or radiotherapy, we performed a meta-analysis based on individual patient data (IPD) from patients treated for newly diagnosed HL. OBJECTIVES: We investigated several questions concerning possible changes in the risk of secondary malignancies when modifying chemotherapy or radiotherapy (omission of radiotherapy, reduction of the radiation field, reduction of the radiation dose, use of fewer chemotherapy cycles, intensification of chemotherapy)...
September 13, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28898338/-response-to-abvd-chemotherapeutic-protocol-in-patients-with-early-stage-hodgkin%C3%A2-s-lymphoma
#17
Javier Díaz, Katherine Soto, Daniel Ernst
BACKGROUND: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. AIM: To report the experience in the treatment of ESHL. MATERIAL AND METHODS: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015...
May 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28832956/early-stage-hodgkin-lymphoma-outcomes-after-combined-modality-therapy-according-to-the-post-chemotherapy-5-point-score-can-residual-pet-positive-disease-be-cured-with-radiotherapy-alone
#18
Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, Yasuhiro Oki, Mani Akhtari, Osama Mawlawi, Naveen Garg, Jillian R Gunther, Jay P Reddy, Grace L Smith, Eric Rohren, Frederick B Hagemeister, Hun J Lee, Luis E Fayad, Wenli Dong, Eleanor M Osborne, Zeinab Abou Yehia, Michelle Fanale, Bouthaina S Dabaja
Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT). We determined freedom from progression (FFP) in patients treated with ABVD and RT according to the eoc-PET-CT 5-point score (5PS). Secondarily, we assessed whether patients with a positive eoc-PET-CT (5PS of 4-5) can be cured with RT alone. The cohort comprised 174 patients treated for stage I-II HL with ABVD and RT alone...
November 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28768235/infradiaphragmatic-hodgkin-lymphoma-a-large-series-of-patients-staged-with-pet-ct
#19
Cédric Rossi, Morgane Mounier, Pauline Brice, Violaine Safar, Emmanuelle Nicolas-Virelizier, Philippe Rey, Aspasia Stamatoullas-Bastard, Marion Alcantara, Adrien Chauchet, Emilie Reboursière, Lauriane Filliatre, Aurore Perrot, Sylvain Garciaz, Gilles Salles, Bertrand Coiffier, Hervé Ghesquières, René-Olivier Casasnovas
INTRODUCTION: Infradiaphragmatic Hodgkin Lymphoma (IDHL) accounts for 3-11% of adult cases of stage I-II Hodgkin Lymphoma and the treatment strategy in IDHL is still heterogeneous. All previous published studies were conducted before the PET-CT era. PET may provide a more accurate evaluation of IDHL stage. The aim of this study was to analyze the clinical and biological characteristics of IDHL patients staged by CT scan or PET-CT in eight French hematology departments and their impact on outcomes in these patients...
July 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28744882/epstein-barr-virus-positivity-is-associated-with-angiogenesis-in-and-poorer-survival-of-patients-receiving-standard-treatment-for-classical-hodgkin-s-lymphoma
#20
Young Wha Koh, Jae-Ho Han, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
Epstein-Barr virus (EBV) is a significant contributor to the development of classical Hodgkin's lymphoma (cHL). Recent studies have documented associations between angiogenesis and EBV-associated malignancies. No study has yet examined the associations among, and prognostic implications of, EBV infection, vascular endothelial growth factor (VEGF) expression, and microvessel density (MVD) in cHL patients. Diagnostic tissues from 135 cHL patients treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) were retrospectively evaluated by in situ hybridization of EBV-encoded small RNA (EBER) and immunohistochemical staining for VEGF and CD31 (a measure of MVD)...
July 26, 2017: Hematological Oncology
keyword
keyword
71275
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"